Advanced Search

Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2011 October;52(5) > The Journal of Cardiovascular Surgery 2011 October;52(5):661-7

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

 

The Journal of Cardiovascular Surgery 2011 October;52(5):661-7

 REVIEWS

Cordis INCRAFT™ ultra-low profile AAA stent-graft system

Torsello G. 1, Brunkwall J. 2, Scheinert D. 3

1 Department of Vascular and Endovascular Surgery, University of Münster, Münster, Germany;
2 Department of Vascular Surgery, University of Cologne, Cologne, Germany;
3 Center for Vascular Medicine, Park Hospital and Heart Center, Leipzig, Germany

Endovascular repair was originally introduced as a less invasive alternative in less healthy patients, but potentially lower morbidity has been balanced by limited anatomic applicability, as well as inferior long-term device durability. The INCRAFT™ endograft was developed with surgical repair in mind, in an attempt to capitalize on the anatomic flexibility of traditional procedures. The INCRAFT system was designed to address durability issues of older generation devices. At the same time it provides a solution for a broad range of patients using a limited number of codes needed. The 3-pieces modular system allows precise placement at level of the iliacs and aortic neck reducing the risk of unintentional coverage of the hypogastric and renal arteries. In addition, the ultra-low profile delivery system (13 Fr even for graft main bodies up to 30 mm) contributes to increase patient eligibility for endovascular aortic repair and to decrease the risk for access complications. When desired, the delivery system can be introduced through a percutaneous approach. The initial experience with the new endograft showed a highly versatile device that offers a more individualized endovascular option to a greater number of patients with abdominal aortic aneurysms. The ongoing IN-NOVATION trial and two planned clinical trials (IN-CEPTION and IN-SPIRATION) will build further understanding of the performance of the device allowing for a wider subset of inclusion criteria.

language: English


FULL TEXT  REPRINTS

top of page